Eli Lilly and Co.
Pays vs peer median
×1.43
+43% premium
Sample
16
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| metabolic | ×0.89 | 3 |
| gastroenterology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×1.33 | 8 |
| phase 2 | ×1.50 | 5 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | cleminorexton | Centessa Pharmaceuticals | sleep disorder | unknown | — | $6.3B |
| 2026 | Centessa portfolio | Centessa | sleep disorders | unknown | $6.3B | $6.3B |
| 2026 | — | Insilico Medicine Inc. | metabolic | preclinical | $115M | $2.9B |
| 2026 | Cleminorexton (ORX750) — full company acquisition | Centessa Pharmaceuticals | narcolepsy | phase_2 | $6.3B | $7.8B |
| 2026 | — | Insilico Medicine | — | preclinical | $115M | $2.9B |
| 2026 | AI-driven discovery | Insilico | — | discovery | $115M | $2.8B |
| 2026 | AI-driven oral therapeutics | Insilico Medicine | — | discovery | $115M | $2.9B |
| 2025 | Ixo-vec | Adverum Biotechnologies | wet age-related macular degeneration | unknown | — | $260M |
| 2025 | antibodies targeting ALS and FTD | Alchemab | ALS and FTD | unknown | — | $415M |
| 2025 | solid_tumors | Aktis Oncology | solid_tumors | preclinical | $1.4B | $1.4B |
| 2025 | STAC-BBB AAV capsid | Sangamo | CNS disorders | preclinical | $18M | $1.4B |
| 2025 | long-acting GLP-1 and incretin delivery technology | Camurus | metabolic disorders | preclinical | — | $870M |
| 2025 | STC-004 | SiteOne Therapeutics | pain | phase_1 | — | $1.0B |
| 2025 | ATLX-1282 | Alchemab Therapeutics | Amyotrophic lateral sclerosis (ALS) | preclinical | $50M | $415M |
| 2025 | OLX75016 | OliX Pharmaceuticals | MASH | phase_1 | — | $630M |
How this is computed
For each Eli Lilly and Co. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 16 disclosed deal premiums vs. peer medians. Raw premium 1.428, clamped to [0.7, 1.5].